/SPPH

SPPH Stock - Spencer Pharmaceutical Inc.

Q: What is the analyst price target for SPPH?

Analyst price target information is not currently available for SPPH.

Q: What is SPPH's market cap?

Market capitalization information is not currently available for SPPH.

Healthcare|Medical - Pharmaceuticals|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SPPH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2001

FY2002

FY2003

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.69

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2003	FY2002	FY2001
Revenue	N/A	$2.62M	$941,372
Gross Profit	N/A	$2.62M	$941,372
Gross Margin	N/A	100.0%	100.0%
Operating Income	$862,541	$2.28M	$2.24M
Net Income	$-862,541	$-2,239,636	$-2,225,623
Net Margin	N/A	-85.3%	-236.4%
EPS	$-1.00	$-3.00	$-3.25

Company Overview

Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.

Frequently Asked Questions about SPPH

What is SPPH's current stock price?

Spencer Pharmaceutical Inc. (SPPH) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for SPPH?

No analyst price targets are currently available for this stock.

What sector is Spencer Pharmaceutical Inc. in?

Spencer Pharmaceutical Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the OTC exchange.

What is SPPH's market cap?

Spencer Pharmaceutical Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does SPPH pay dividends?

No, Spencer Pharmaceutical Inc. does not currently pay a dividend to shareholders.